Cardiotoxicity from doxorubicin — one of oncology's most effective but damaging chemotherapeutics — remains a poorly solved problem that forces clinicians to choose between cancer control and cardiac health. Evidence that the heart's own microenvironment harbors protective stem cells capable of countering this toxicity could reshape how cardioprotection is approached in cancer patients.
This in vitro study isolated Sca-1+/Nanog+ stem cells from human pericardial fluid and collected their conditioned medium (hPFCs-CM) — the secreted molecular cocktail these cells produce — then applied it to AC16 human cardiomyocytes damaged by doxorubicin. Cells treated with DOX showed significantly elevated reactive oxygen species and apoptosis rates compared to controls. Exposure to hPFCs-CM measurably attenuated both oxidative stress and cell death. Transcriptomic sequencing identified 52 differentially expressed genes distinguishing the DOX-damaged from the hPFCs-CM-treated groups. Among three candidate genes validated by RT-qPCR — MYH3, IFI16, and KCTD14 — siRNA knockdown of MYH3 (a myosin heavy chain isoform typically associated with embryonic muscle development) significantly amplified the conditioned medium's anti-apoptotic effect, implicating MYH3 as a molecular checkpoint modulating cardiac cell survival.
Pericardial fluid as a reservoir of cardioprotective stem cells is a relatively nascent concept, and its translational appeal is genuine — pericardial fluid is already routinely collected during cardiac surgery, making Sca-1+/Nanog+ cell isolation a clinically feasible proposition. However, the study's limitations are substantial. All experiments were conducted in a single human cardiomyocyte cell line, with no animal or ex vivo cardiac tissue validation. The conditioned medium's active paracrine constituents — whether exosomes, cytokines, or growth factors — remain uncharacterized, leaving the mechanistic chain from MYH3 suppression to reduced apoptosis incompletely resolved. This represents incremental but directionally interesting preclinical work, warranting replication in three-dimensional cardiac models or in vivo systems before its translational significance can be properly gauged.